LATHAM, N.Y. — AngioDynamics, a medical technology company specializing in vascular treatments and cancer care, has appointed Eric Honroth as President and Chief Executive Officer, effective Nov. 2, 2026.
Honroth will also join the company’s Board of Directors, succeeding Jim Clemmer, who is retiring after 10 years as President and CEO. Clemmer will leave the board on Nov. 2 but remain with the company in a consulting role to support the leadership transition.
Honroth brings more than 20 years of leadership experience in the medical device and life sciences industries, including cardiovascular, endovascular, urology and oncology markets.
Most recently, he served as Global President of Life Science at Getinge. He previously led the company’s $1.2 billion North American business, overseeing growth initiatives, product development and operational improvements.
Earlier in his career, Honroth held senior leadership positions at Abbott Vascular, Becton Dickinson, CareFusion and Boston Scientific. His experience includes managing large commercial organizations and global business operations.
“AngioDynamics enters this transition with real momentum, including a high-growth Med Tech segment, a strong balance sheet with no outstanding debt, and an operational transformation that is delivering,” said Howard Donnelly, AngioDynamics Board Chair. “Eric has done what this moment requires. He has built businesses, driven profitable growth, and managed global operations with responsibility for both revenue and cost structure.”
Donnelly also praised Clemmer’s leadership, crediting him with helping transform AngioDynamics into a more focused medical technology company while strengthening its operational performance.
“On behalf of the Board, I want to thank Jim for his exceptional leadership over the past decade,” Donnelly said. “Under his guidance, AngioDynamics underwent a successful transformation that sharpened our focus and built a solid foundation for sustainable growth and profitability.”
Honroth said he looks forward to building on the company’s existing technology portfolio and expanding its market opportunities.
“I am honored to lead AngioDynamics at such an important moment for the Company and grateful for the confidence the Board and Jim have placed in me,” Honroth said. “The Company has a differentiated technology portfolio, multiple growth drivers, and an exceptionally talented team. I look forward to working with employees and customers to build on this foundation and accelerate progress where we see the greatest opportunities to improve patient care and create shareholder value.”
Clemmer said he is confident in Honroth’s ability to guide the company’s next stage of development.
“It has been the privilege of my career to lead AngioDynamics these past ten years,” Clemmer said. “Together, we sharpened the Company’s focus, expanded operating capabilities, and positioned the business for its next phase of growth. I am confident Eric’s experience and leadership make him the right person to carry that work forward, and I look forward to supporting a smooth transition.”
AngioDynamics develops medical technologies designed to restore blood flow, expand cancer treatment options and improve patient outcomes.
